Acorda Therapeutics 8-K 2010
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 3, 2010
Acorda Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (914) 347-4300
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On February 3, 2010, Acorda Therapeutics, Inc. issued a press releasing announcing that the wholesale acquisition cost (WAC) for AMPYRA (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. The press released also announced the establishment of a comprehensive set of services to ensure broad access to AMPYRA for people with MS, including patient assistance and co-pay programs.
Item 9.01 Financial Statements and Exhibits
99.1 Press Release dated February 3, 2010.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.